The global pancreatic cancer therapeutics and diagnostics market size reached US$ 4.3 Billion in 2023. Looking forward, the market is projected to reach US$ 7.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.53% during 2023-2032. The burgeoning healthcare industry, rising prevalence of pancreatic cancer, and the escalating demand for chemotherapy to kill pancreatic cancer cells represent some of the key factors driving the market.
Pancreatic cancer therapeutics and diagnostics are medical procedures used to diagnose pancreatic cancer and provide treatment. These therapeutics and diagnostics comprise ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. They rely on an endoscopic ultrasound (EUS) that uses an ultrasound device to produce images of the pancreas from inside the abdomen. They help in monitoring the location of the tumor due to an uncontrollable growth of cells in the pancreas.
They assist in performing a biopsy to remove a small sample of tissue for examination under a microscope. They also aid in laboratory investigations, such as a complete blood count (CBC), liver enzyme tests for biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. As a result, pancreatic cancer therapeutics and diagnostics find applications in hospitals and specialty centers across the globe.
Moreover, governing agencies of several countries are extensively investing in pancreatic cancer clinical trial testing and deoxyribonucleic acid (DNA) repair inhibitors combined with chemotherapy. They are also focusing on enhancing the growth of pancreatic cancer therapeutics and diagnostics by approving drugs in the clinical phase. Apart from this, key players operating in the industry are introducing a humanized monoclonal antibody that promotes the anti-tumor immune response for treating esophageal and gastroesophageal junction and pancreatic cancer. They are also developing and introducing kit-based testing to detect pancreatic cancer by determining BRCA1 and BRCA2 variants and assessing genomic instability, which is projected to contribute to the growth of the market in the coming years.
According to the report, North America was the largest market for pancreatic cancer therapeutics and diagnostics. Some of the factors driving the North America pancreatic cancer therapeutics and diagnostics market included advancements in diagnostic technologies, emerging therapies and treatment options, increasing healthcare expenditure, and government initiatives and funding.
Pancreatic cancer therapeutics and diagnostics are medical procedures used to diagnose pancreatic cancer and provide treatment. These therapeutics and diagnostics comprise ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. They rely on an endoscopic ultrasound (EUS) that uses an ultrasound device to produce images of the pancreas from inside the abdomen. They help in monitoring the location of the tumor due to an uncontrollable growth of cells in the pancreas.
They assist in performing a biopsy to remove a small sample of tissue for examination under a microscope. They also aid in laboratory investigations, such as a complete blood count (CBC), liver enzyme tests for biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. As a result, pancreatic cancer therapeutics and diagnostics find applications in hospitals and specialty centers across the globe.
Pancreatic Cancer Therapeutics and Diagnostics Market Trends
At present, the rising prevalence of pancreatic cancer due to the increasing geriatric population and excessive smoking habits among the masses represents one of the key factors supporting the growth of the market. Besides this, there is an increase in the development of molecular biology, drugs, and diagnostic technology around the world. This, along with the thriving healthcare industry, is currently propelling the growth of the market. In addition, the escalating demand for chemotherapy to kill pancreatic cancer cells by preventing them from growing and dividing is positively influencing the market.Moreover, governing agencies of several countries are extensively investing in pancreatic cancer clinical trial testing and deoxyribonucleic acid (DNA) repair inhibitors combined with chemotherapy. They are also focusing on enhancing the growth of pancreatic cancer therapeutics and diagnostics by approving drugs in the clinical phase. Apart from this, key players operating in the industry are introducing a humanized monoclonal antibody that promotes the anti-tumor immune response for treating esophageal and gastroesophageal junction and pancreatic cancer. They are also developing and introducing kit-based testing to detect pancreatic cancer by determining BRCA1 and BRCA2 variants and assessing genomic instability, which is projected to contribute to the growth of the market in the coming years.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global pancreatic cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2024-2032. The report has categorized the market based on type and application.Type Insights:
- Diagnostics
- Imaging
- Biopsy
- Endoscopic Ultrasound
- Others
- Treatment
- Targeted Therapies
- Chemotherapy
- Surgery
- Others
Application Insights:
- Hospitals
- Clinics
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
According to the report, North America was the largest market for pancreatic cancer therapeutics and diagnostics. Some of the factors driving the North America pancreatic cancer therapeutics and diagnostics market included advancements in diagnostic technologies, emerging therapies and treatment options, increasing healthcare expenditure, and government initiatives and funding.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global pancreatic cancer therapeutics and diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies include AstraZeneca plc, F. Hoffmann-La Roche Ltd., Immunovia AB, Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
- How has the global pancreatic cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global pancreatic cancer therapeutics and diagnostics market?
- What are the key regional markets?
- Which countries represent the most attractive pancreatic cancer therapeutics and diagnostics markets?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the pancreatic cancer therapeutics and diagnostics market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the pancreatic cancer therapeutics and diagnostics market?
- What is the competitive structure of the global pancreatic cancer therapeutics and diagnostics market?
- Who are the key players/companies in the global pancreatic cancer therapeutics and diagnostics market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Pancreatic Cancer Therapeutics and Diagnostics Market
6 Market Breakup by Type
7 Market Breakup by Application
8 Market Breakup by Region
9 Drivers, Restraints, and Opportunities
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- Immunovia AB
- Novartis AG
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 4.3 Billion |
| Forecasted Market Value ( USD | $ 7.6 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 5 |
